Mounjaro (tirzepatide) has emerged as one of the most impactful brands in the GLP‑1 category, showing remarkable traction over the last nine months. With growing acceptance among clinicians and increasing awareness among patients, Mounjaro’s performance reflects both strong clinical confidence and rising demand in the metabolic therapy space.
During the January-December 2025 period, tirzepatide (Mounjaro) recorded sales of approximately Rs. 601 crore, placing it among the top contributors within the GLP‑1 segment. A significant share of this revenue was generated in the last nine months of the year, indicating accelerating adoption rather than front‑loaded sales. This momentum suggests that Mounjaro benefited from progressive physician confidence with real‑world outcomes, wider patient acceptance after the initial launch phase and strong positioning versus older GLP‑1 therapies.
Mounjaro’s dual GIP/GLP‑1 receptor agonist mechanism has differentiated it from traditional GLP‑1 drugs. Over the last nine months, this differentiation translated into higher prescriptions, especially for patients with type 2 diabetes and obesity who were not achieving targets with single‑pathway therapies.
Unlike many specialty drugs that see gradual uptake, Mounjaro demonstrated faster‑than‑expected penetration. The last nine months showed consistent month‑on‑month growth, reflecting repeat prescriptions and therapy continuation.
The broader shift in diabetes and weight‑management treatment paradigms supported Mounjaro’s rise. As prescribers increasingly favored injectable incretin‑based therapies, Mounjaro stood out as a next‑generation option.
Within the GLP‑1 landscape, Mounjaro competed with established brands such as semaglutide‑based therapies. Despite this competition, its strong performance in the last nine months highlights rapid brand recall, Willingness of physicians to switch eligible patients and growing preference for higher efficacy outcomes. Its near Rs 600 crore annualized run rate underscores how quickly it closed the gap with long‑standing market leaders.
The last nine months were not just about revenue growth but about market validation. Mounjaro transitioned from a promising entrant to a mainstream therapy choice. Sustained demand during this period indicates that growth was driven by clinical value rather than short‑term promotional push.
Mounjaro’s performance over the last nine months highlights one of the most successful recent launches in the metabolic therapy segment. With strong sales traction, differentiated efficacy, and increasing physician trust, it has firmly established itself as a key growth engine within the GLP‑1 market and a benchmark for future innovations in this space.
Note : Sales figures are based on January–December 2025 data, with the last nine months contributing the majority share.
